In the evaluation of efficacy of a vaccine to protect against disease caused by finitely many diverse infectious pathogens, it is often important to assess if vaccine protection depends on variations of the exposing pathogen. This problem can be formulated under a competing risks model where the endpoint event is the infection and the cause of failure is the infecting strain type determined after the infection is diagnosed. The strain-specific vaccine efficacy is defined as one minus the cause-specific hazard ratio (vaccine/placebo). This paper develops some simple procedures for testing if the vaccine affords protection against various strains and if and how the strain-specific vaccine efficacy depends on the type of exposing strain, adjus...
For time-to-event data with finitely many competing risks, the propor-tional hazards model has been ...
In influenza vaccination studies assessing vaccine efficacy (VE), both specific and non-specific end...
Vaccine effect, as measured in clinical trials, may not accurately reflect population-level impact. ...
Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiv...
(See the editorial commentary by Sadoff and Wittes, on pages 1279–81.) A central goal of vaccine res...
common diseases using case-control and cohort studies. Internationa/Journal of Epidemiology 1984,13:...
We performed computer simulations to study the effects of prior infection on vaccine efficacy. We in...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
The authors consider estimability and interpretation of vaccine efficacy based on time to event data...
The fact that many pathogens can be carried or shed without causing symptoms complicates the interpr...
Influenza is an infectious seasonal disease against which yearly vaccination is recommended, especia...
“Leaky” vaccines are those for which vaccine-induced protection reduces infection rates on a per-exp...
Abstract Background The use of correlates of protection (CoPs) in vaccination trials offers signific...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Vaccine response is often random because of possible vaccine failures and variation in the immune sy...
For time-to-event data with finitely many competing risks, the propor-tional hazards model has been ...
In influenza vaccination studies assessing vaccine efficacy (VE), both specific and non-specific end...
Vaccine effect, as measured in clinical trials, may not accurately reflect population-level impact. ...
Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiv...
(See the editorial commentary by Sadoff and Wittes, on pages 1279–81.) A central goal of vaccine res...
common diseases using case-control and cohort studies. Internationa/Journal of Epidemiology 1984,13:...
We performed computer simulations to study the effects of prior infection on vaccine efficacy. We in...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
The authors consider estimability and interpretation of vaccine efficacy based on time to event data...
The fact that many pathogens can be carried or shed without causing symptoms complicates the interpr...
Influenza is an infectious seasonal disease against which yearly vaccination is recommended, especia...
“Leaky” vaccines are those for which vaccine-induced protection reduces infection rates on a per-exp...
Abstract Background The use of correlates of protection (CoPs) in vaccination trials offers signific...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Vaccine response is often random because of possible vaccine failures and variation in the immune sy...
For time-to-event data with finitely many competing risks, the propor-tional hazards model has been ...
In influenza vaccination studies assessing vaccine efficacy (VE), both specific and non-specific end...
Vaccine effect, as measured in clinical trials, may not accurately reflect population-level impact. ...